UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 137

of 'Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects'

137
TI
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
AU
Allen JA, Adlakha A, Bergethon PR
SO
Arch Neurol. 2006;63(10):1475.
 
OBJECTIVE: To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor.
DESIGN: Case report/literature review.
SETTING: University hospital.
PATIENT: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.
RESULTS: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.
CONCLUSIONS: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur.In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.
AD
Department of Neurology, Tufts -- New England Medical Center, Boston, Mass, USA.
PMID